One-Shot gene therapy aims to end monthly eye injections for wet AMD
Disease control
Not yet recruiting
This early-stage trial tests EXG202, a gene therapy given as a single injection into the eye for people with wet age-related macular degeneration (AMD). The goal is to see if it is safe and can produce a protein that blocks abnormal blood vessel growth long-term, potentially redu…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC